肿瘤细胞治疗研究
英文原题：Synchronous presentation of pH+ B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia treated with blinatumomab.
采用单克隆抗体和CAR-T（CAR-T）细胞疗法的 CD19 靶向免疫治疗，已在复发/难治性非霍奇金淋巴瘤（NHL）和慢性淋巴细胞白血病（CLL）中显示出治疗疗效。
靶向CD19的单克隆抗体和CAR-T（CAR-T）细胞疗法已在非霍奇金淋巴瘤（NHL）和慢性淋巴细胞白血病（CLL）的复发/难治情境中显示疗效。然而，靶向CD19的T细胞接合双特异性抗体blinatumomab目前仅获批用于B细胞急性淋巴细胞白血病（ALL），在CLL等其他临床情境中的研究很少。我们报告一例同时患有费城染色体阳性（Ph+）ALL和CLL的患者，接受blinatumomab治疗后，两种疾病均达到微小残留病（MRD）阴性缓解。
CD19 directed immunotherapy with monoclonal antibodies and chimeric antigen receptor T (CAR-T) cell therapy has shown treatment efficacy in the relapsed/refractory setting for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the CD19 directed bispecific T-cell engager, blinatumomab, is currently only approved in B-cell acute lymphoblastic leukemia (ALL) and has largely not been investigated in other clinical contexts for CLL. We report a case of a patient who presented with both Philadelphia chromosome positive (pH+) ALL and CLL who achieved measurable residual disease (MRD) negative remission for both diseases with blinatumomab.
MEMBER ACCOUNT
登录成功会直接打开下一页。
